Robert Rapaport
Pediatric Endocrinology · New York, NYNPI 1073580858
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.8%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 23.2%. Among pediatric endocrinology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 56 payments — averaging $1757.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Hexal AG$23K
- Biomarin Pharmaceutical Inc.$22K
- OPKO Pharmaceuticals, LLC$20K
- Novo Nordisk$11K
- Novo Nordisk Health Care AG$9K
- Pfizer$9K
- plus $5K from 5 others
Across 103 payments — averaging $2192.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$50K
- Biomarin Pharmaceutical Inc.$38K
- Ascendis Pharma Endocrinology Inc$24K
- Janssen Research & Development, LLC$23K
- AbbVie$18K
- Boehringer Ingelheim$18K
- plus $54K from 6 others
What the payments were for
- Consulting fees$52,93154%
- Speaking & faculty fees$15,10015%
- Travel & lodging$28,06529%
- Food & beverage$2,2782%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Hexal AG | 12 | $22,802 |
| Biomarin Pharmaceutical Inc. | 12 | $21,699 |
| OPKO Pharmaceuticals, LLC | 3 | $19,513 |
| Novo Nordisk | 7 | $10,872 |
| Novo Nordisk Health Care AG | 4 | $9,483 |
| Pfizer | 10 | $8,867 |
| Ferring Pharmaceuticals Inc. | 4 | $3,273 |
| Eton Pharmaceuticals, Inc. | 1 | $1,750 |
| Kyowa Kirin, Inc. | 1 | $98 |
| Ipsen Biopharmaceuticals, Inc | 1 | $47 |
| Insulet Corporation | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNITROPE$22,611
- VOXZOGO 1.2mg$21,412
- Sogroya$9,426
- NGENLA$8,286
- Norditropin$6,120
- ZOMACTON$3,226
- Alkindi$1,750
- KHINDIVI$1,750
- INCRELEX$1,750
- GENOTROPIN$281
How this compares
$98,421 in reported general payments places this provider in the 95th percentile of 138 pediatric endocrinology providers in New York.
Other pediatric endocrinology in New York
- Christopher RomeroNew York$35K
- Vidhu ThakerNew York$33K
- Natasha LeibelNew York$24K
- Mabel YauNew York$19K
- Ilene FennoyNew York$19K
- Emily BreidbartNew York$18K
- Madeleine HarbisonNew York$12K
- Charles SklarNew York$12K
- Oksana LekarevNew York$11K
- Mary GallagherNew York$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.